NEW YORK (GenomeWeb News) – CombiMatrix will net an additional $1.2 million in funding after its stockholders approved the sale of the company's Series C Preferred Stock, the company said today.

CombiMatrix raised $1.2 million in a first tranche of equity financing in May. The second tranche of that financing was subject to stockholder approval, which was granted at the firm's annual meeting, held on June 27.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.